The Microdose Array Print (MAP) Technology has shown potential in clinical trials, providing the possibility of more accurate ocular drug delivery than traditional eye droppers

NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) — While medical devices have seen incredible advancements over the last 100 years, ocular drug delivery systems have seen minimal progress; the standard vision dropper used today has gone largely unchanged in the last century. Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the pipeline of late-stage microdose array print (MAP™) therapeutics, is developing one of the first microdosing systems that aims in order to improve the overall patient experience and streamline practice flow by facilitating digital shipping of attention medications.

The particular investigational delivery device is currently only used in clinical study settings and has shown promise in delivering cleaner and more efficient ocular drug shipping. “The proprietary Eyenovia device takes a novel approach to administering eye medication via microdosing and does it inside a way that should improve the patient experience, ” said Michael Rowe, CEO associated with Eyenovia. “Traditional eye droppers are cumbersome, inaccurate, and prone to contamination. Even when handled with care, there’s still the significant likelihood that medicine patients are paying for gets wasted due to missing drops. ”

The device is uniquely designed with no protruding parts plus a recessed nozzle to not touch patients’ eyes, reducing the probability of infection. Eyenovia also expects a more gentle dosing experience to create a fundamental paradigm shift in eye care.

Eye drop innovation has stagnated, in part due to changing medical device regulations that complicate patient access to innovative devices. Safety takes precedence in the particular medical gadget industry; however, as digital innovation leaps ahead of bureaucratic regulatory bodies, regulators are usually challenged in order to keep pace with the cutting-edge new products that will push the particular boundaries of technology.

While the world associated with healthcare looked significantly different 100 years ago, similar paradigm shifts in healthcare technology through innovations like pacemakers, cochlear implants, 3-D printed body parts, and artificial hearts revolutionized their respective industries, greatly improving quality of life plus patient treatment. With a market share valued at roughly €100 billion in Europe , medical products make up 7. 5% of healthcare expenditure inside most publicly funded health care systems, and the American ecosystem is taking notice.

As American private venture capital makes inroads into the electronic health market, the total capital investment within medical gadgets has increased by a factor of five , which portends a promising future for improved patient care. Medical technology device advancement is only expected to increase over the next five many years, and Eyenovia is one associated with those industry leaders in championing innovation.

“We’re proud to be innovating in this space where we have the potential to make lives easier with regard to millions of Americans and people worldwide suffering from chronic eye conditions, ” adds Rowe.

For more information, visit eyenovia. com .

About Eyenovia, Incorporation.

Eyenovia , Inc. is a pre-commercial ophthalmic technologies company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications regarding mydriasis, presbyopia and myopia progression. For more information, visit .

Forward-Looking Statements

Except intended for historical info, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other claims relating to our future activities or other long term events or even conditions, including estimated marketplace opportunities to get our product candidates plus platform technology. These statements are based on current expectations, estimates and projections about our own business based, in part, on assumptions made by management. These statements are not guarantees of upcoming performance and involve risks, uncertainties plus assumptions that are difficult to predict. Therefore , actual outcomes and results may, and in some cases are likely in order to, differ materially from what is expressed or forecasted in the particular forward-looking statements because of numerous factors discussed from time to time inside documents which usually we file with the U. S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical tests, including, but not limited to, the costs, design, initiation plus enrollment (which could still be adversely impacted simply by COVID-19), timing, progress and results of this kind of trials; the timing associated with, and the ability to submit applications pertaining to, obtaining plus maintaining regulatory approvals meant for our item candidates; the potential impacts of COVID-19 on our supply chain; the possible advantages of our product candidates and platform technology; the particular rate and degree associated with market acceptance and clinical utility of our product candidates; our own estimates regarding the potential market opportunity designed for our item candidates; reliance on third parties in order to develop plus commercialize the product applicants; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization plus marketing capabilities and techniques for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate as well as the impact of these changes on this ability to obtain regulating approval just for our products; and our own competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws. Eyenovia does not undertake any obligation in order to update any kind of forward-looking claims.

Contact Information:
Norbert Lowe
Vice President, Commercial Operations
[email protected] com

Buse Kayar
[email protected] com

Related Images

Image 1: Eyenovia


This content was issued through the press release distribution service in Newswire. possuindo .




Leave a Reply

Your email address will not be published. Required fields are marked *